Becton, Dickinson and Company (BD) has reported revenues of $19.5bn in fiscal year 2026 (FY26), reflecting a 4.9% rise year-over-year (YoY).
The company expects FY27 earnings to fall in the $13.10 to $13.30 per share range. BD released its financials ahead of market open. The company’s stock, listed on the New York Stock Exchange (NYSE) was largely unchanged at market open on 5 November, but soon rose to $214.04 (correct as of 10am ET). BD has a market cap of around $58bn.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
BD’s strongest performing segment in FY26 was medical essentials. Occupying pole position on its balance sheet, the segment rose 4.6% YoY to around $3.9bn, closely followed by interventional, rising 6.7% YoY to around $3.8bn, and connected care at around $3.5bn. While BD’s BioPharma Systems segment contributed the smallest proportion of its FY26 revenues at $771m, it saw the biggest YoY growth at 17%.
Coinciding with the release of its FY26 financials, BD also released its Q4 results. Coming in at $5.3bn, the Q4 total reflected a 5.4% uptick YoY.
Reflecting on BD’s financial performance, the company’s president and CEO, Tom Polen, called FY26 a “defining year” given that BD completed its transformation towards becoming a more focused medtech company following the separation of its life sciences business.
BD reached an agreement to spin out its Biosciences and Diagnostic Solutions business and merge it with Waters Corporation’s diagnostics business in June 2025. The bumper deal, valued at $17.5bn, completed in February 2026.
GlobalData analysts highlighted at the time that BD’s biosciences and diagnostic solutions unit was a business worth approximately $3.3bn that generated around 5% annual growth from 2019 to 2024. In addition, GlobalData analysis highlighted that the revenue profile of BD’s business was notably durable, with around 80% recurring, supported by a large installed base and ongoing demand for consumables, reagents, and service.
Continuing his comments on the past year, Polen said: “We strengthened our core growth and expanded BD Excellence to elevate our commercial capabilities, accelerate innovation and drive greater productivity. We enter fiscal 2027 from a position of strength, with a portfolio built for durable performance and confidence in the long-term growth, earnings and cash-flow potential of New BD.”
